1. UCB Inspired by patients. Driven by science.
BioTrinity 2016

2. UCB: making lives better every day
Bringing solutions to people living with neurological or immunological diseases
Key facts and figures (2015):
Revenue: €3.88 billion
rEBITDA: €821 million
More than 7500 employees globally
Operations in ~40 countries
R&D Spend: 27% of revenue
Listed on Euronext

3. UCB: reinventing itself, leveraging a solid heritage
1972: A new state-of-the-art R&D center in Braine-l’Alleud, Belgium
Today
2006: UCB acquires German pharma company Schwarz Pharma
1928: Emmanuel Janssen establishes UCB in Brussels
1990s: approval of Keppra®, a novel
anti-epileptic
Combine leadership in antibody research & chemistry expertise to better treat severe diseases
1952: UCB discovers Atarax® U.S. license awarded to Pfizer
2004: UCB acquires British biotech company Celltech
Launch of Cimzia®, Vimpat® & Neupro® (CVN)
1980s: UCB registers its novel antihistamine Zyrtec®
1936: UCB enters the United States
1928
1936
1952
1972
1980s
1990s
2004
2006
Today
Chemical Group
Primary Care Pharma
Specialty Bio-pharma

4. Growth Drivers:
Core medicines tracking well towards peak sales target of € 3.1 billion*
EXPECTED AT LEAST €
1.5
billion peak sales
Inflammatory arthritis indications and Crohn’s disease
Psoriasis: strategic collaboration with Dermira
1.2
Epilepsy Partial-Onset Seizures
Monotherapy in the U.S.
Partner in Japan: Daiichi Sankyo
400
million peak sales
Parkinson’s disease and Restless Legs Syndrome
Partner in Japan: Otsuka
* By the end of this decade

5. Briviact® (brivaracetam) in epilepsy POS1
Epilepsy seizure reduction in treatment resistant patients
Approved in Europe (Jan. 2016) and in the U.S. (Feb. 2016)
Guoqiong, living with epilepsy
One of the largest Phase 3 programs in epilepsy
Extensive clinical data: Over 3000 patients involved in the trials; 212 non-clinical studies, 51 clinical studies
Statistically significant AND clinically relevant top-line results²
1 POS: partial-onset seizures
2 The most commonly reported adverse events were somnolence, dizziness, fatigue and headache. Source: UCB data on file
3 American Epilepsy Society

6. A promising pipeline for differentiating solutions
Phase 1
Phase 2
Phase 3
Filing
romosozumab
Osteoporosis
bimekizumab / UCB4940 (IL17AF)
Immunology indications
Phase 2b start: H2 2016
bimekizumab add-on to Cimzia®
rheumatoid arthritis
Phase 2a results: H1 2017
UCB0942 (PPSI)
highly drug resistant epilepsy
Phase 2a results: Q1 2017
seletalisib (PI3K Delta inhibitor)
dapirolizumab pegol (CD40L antibody)
systemic lupus erythematosus
Phase 2b start: Q3 2016
(Partner: Biogen)
UCB7665
Phase 2 start: Q2 2016
UCB4144 / VR942
asthma
(Partner: Vectura)
UCB1332 / NPT200-11
Parkinson’s disease
(Partner: Neuropore)
UCB6673 Immunology indications
(Partner: King’s College London)
(Partner: Amgen)
neurology
immunology

7. Cutting-edge research and science
Addressing unmet patient needs and delivering breakthrough medicines
Two main Research Centers
World-class expertise in selected therapeutic areas and disease mechanisms
Connecting science in new ways - chemistry (small, chemically-derived molecules) and biology (large antibody-based molecules),
to leverage the potential of these two disciplines
‘Open innovation’ model based on strong partnerships with other biotech companies and prominent universities
Biologics pilot plant – Braine-l’Alleud, Belgium
Biologics R&D centre - Slough, U.K.
Two main Research Centers

8. UCB’s partnering strategy seeks patient solutions from discovery to commercial stage
NEUROLOGY
Seizure disorders (e.g. refractory epilepsy, rare genetic forms, autoimmune epilepsy, epileptogenesis)
Neurodegenerative diseases (disease modification)
Movement disorders (e.g. disease modifying therapies, non-dopaminergic therapies)
Other diseases primarily treated by neurologists, including orphan indications
IMMUNOLOGY
Autoimmune disorders
Inflammatory diseases
Fibrosis
B-cell diseases
Neuro-inflammatory diseases
Other diseases primarily treated by rheumatologists and other autoimmune/inflammatory disease specialists